利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.027 秒)

    BACTERIAL ENGINEERING
    4.
    发明申请
    BACTERIAL ENGINEERING 审中-公开

    公开(公告)号：US20180135041A1

    公开(公告)日：2018-05-17

    申请号：US15818579

    申请日：2017-11-20

    申请人： David Hugh Williams ,  Arthur Keith Turner ,  John Richard Wain

    发明人： David Hugh Williams ,  Arthur Keith Turner ,  John Richard Wain

    IPC分类号： C12N15/10

    CPC分类号： C12N15/1058 ,  C12N15/102 ,  C12N15/1082

    摘要： Described is a process for producing a mutant bacterium which exhibits improved survival and/or growth under a selected growth condition, the process comprising the steps of: (a) generating a pool of mutant bacteria by transposon mutagenesis with an activating transposon (TnA), wherein the TnA comprises a promoter capable of increasing transcription of a gene at or near its insertion site; (b) growing bacteria from the mutant pool under the selected growth condition and under one or more reference conditions to produce two or more test cultures; and (c) comparing the distribution of TnA insertions between test cultures to identify a first class of genes which are disadvantageous for growth and/or survival under the selected growth condition and a second class of genes which are advantageous for growth and/or survival under the selected growth condition.

    BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE
    6.
    发明申请
    BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE 有权
    双氰胺 - 氨基化合物及其用途

    公开(公告)号：US20100331328A1

    公开(公告)日：2010-12-30

    申请号：US12918266

    申请日：2009-02-19

    申请人： Ian Collins ,  John Charles Reader ,  David Hugh Williams ,  Sukhbinder Singh Klair ,  Jane Elizabeth Scanlon ,  Nelly Piton ,  Michael Cherry

    发明人： Ian Collins ,  John Charles Reader ,  David Hugh Williams ,  Sukhbinder Singh Klair ,  Jane Elizabeth Scanlon ,  Nelly Piton ,  Michael Cherry

    IPC分类号： A61K31/5377 ,  C07D487/04 ,  A61K31/497 ,  A61P35/00 ,  C12N5/00 ,  C07D241/26 ,  A61K31/4965 ,  C07D413/12

    CPC分类号： C07D471/04

    摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:

    摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及下列通式的某些双环芳基 - 芳基胺化合物（本文称为BCAA化合物），其特别地抑制检测点激酶1（CHK1）激酶功能 。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制CHK1激酶功能，以及治疗由CHK1介导的疾病和病症，即 通过抑制CHK1激酶功能等改善，包括增殖条件如癌症等，任选地与另一种试剂组合，例如（a）DNA拓扑异构酶I或II抑制剂; （b）DNA损伤剂; （c）抗代谢物或TS抑制剂; （d）微管靶向剂; 和（e）电离辐射：

    Home network roaming management for eCall-only subscribers
    8.
    发明授权
    Home network roaming management for eCall-only subscribers 有权
    仅适用于eCall用户的家庭网络漫游管理

    公开(公告)号：US08923802B2

    公开(公告)日：2014-12-30

    申请号：US13283970

    申请日：2011-10-28

    申请人： Jean-Baptiste Bertrand Bourdu ,  David Hugh Williams ,  Nikolai Konrad Leung

    发明人： Jean-Baptiste Bertrand Bourdu ,  David Hugh Williams ,  Nikolai Konrad Leung

    IPC分类号： H04M11/04 ,  H04W76/00 ,  H04W4/04 ,  H04W4/22 ,  H04W60/00

    CPC分类号： H04W76/007 ,  H04W4/046 ,  H04W4/90 ,  H04W60/00 ,  H04W76/50

    摘要： A Home Public Land Mobile Network (HPLMN) or home network immediately accepts a registration requests from “eCall-only” subscribers attempting to register with any Visitor Public Land Mobile Networks (VPLMNs) or roaming network. This avoids unnecessary delays in the establishment of an eCall (emergency call) that might be otherwise introduced by the home network's roaming registration management policy (RRMP) that otherwise would only permit registrations (and subsequent call servicing) by preferred roaming VPLMN partners and automatically reject registrations from non-preferred roaming networks (which may hinder or prevent timely completion of an eCall).

    摘要翻译： 家庭公共陆地移动网络（HPLMN）或家庭网络立即接受试图向任何访问者公共陆地移动网络（VPLMN）或漫游网络注册的“仅eCall”用户的注册请求。 这避免了建立可能由家庭网络的漫游注册管理策略（RRMP）另外引入的eCall（紧急呼叫）的不必要的延迟，否则该呼叫只允许首选漫游VPLMN伙伴进行注册（和随后的呼叫服务）并自动拒绝 非首选漫游网络的注册（可能阻碍或阻止及时完成eCall）。

    Bicyclylaryl-aryl-amine compounds and their use
    9.
    发明授权
    Bicyclylaryl-aryl-amine compounds and their use 有权
    双环芳基 - 芳基胺化合物及其用途

    公开(公告)号：US08530468B2

    公开(公告)日：2013-09-10

    申请号：US12918266

    申请日：2009-02-19

    申请人： Ian Collins ,  John Charles Reader ,  David Hugh Williams ,  Sukhbinder Singh Klair ,  Jane Elizabeth Scanlon ,  Nelly Piton ,  Michael Cherry

    发明人： Ian Collins ,  John Charles Reader ,  David Hugh Williams ,  Sukhbinder Singh Klair ,  Jane Elizabeth Scanlon ,  Nelly Piton ,  Michael Cherry

    IPC分类号： A61K31/497 ,  A61K31/5377 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14

    CPC分类号： C07D471/04

    摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation:

    摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及下列通式的某些双环芳基 - 芳基胺化合物（本文称为BCAA化合物），其特别地抑制检测点激酶1（CHK1）激酶功能 。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制CHK1激酶功能，以及治疗由CHK1介导的疾病和病症，即 通过抑制CHK1激酶功能等改善，包括增殖条件如癌症等，任选地与另一种试剂组合，例如（a）DNA拓扑异构酶I或II抑制剂; （b）DNA损伤剂; （c）抗代谢物或TS抑制剂; （d）微管靶向剂; 和（e）电离辐射：